Three different nanopharmaceuticals will be produced within the project after achieving GMP certification for the plant and completing the technology transfer process for each production.
The three of them were selected on the basis of their “technologies readiness level” (TRL) 4-5 and positive commercial evaluation (scalability and intended market).
![]() A short interfering RNA (siRNA) nanoformulation for the topical treatment of ocular pain associated with dry eye syndrome (DES). |
![]() A HIV nanovaccine intended for intranasal administration. |
![]() Hyaluronan spheres, a treatment for interstitial cystitis/painful bladder syndrome (IC/PBS). |
Integration of microfluidics in the plant |
![]()
|
Highly advanced characterization techniques |
![]() Asymmetrical Flow Field Flow Fractionation (A4F) is increasingly used as a mature separation method to size sort and characterize nanoparticles in native conditions, and offers the possibility to analyze a wide variety of macromolecules and particles ranging from the nanometer to the micrometer range with high resolution. This analytical methodology will be used to control/validate the process and finally to characterize the final batches in compliance with GLP, and will complement other standard methods already available in the pilot plant (DLS, SEC, HPLC…). This technique has been already used at lab-scale, but NanoPilot will implement it for the quality control of the production processes.
|